Molecular Partners AG (MOLN) expanded its strategic collaboration with Orano Med to include the development of an additional six targeted alpha radio-therapies for cancer, the companies said Sunday.
The companies entered into an initial agreement in January 2024 to co-develop four programs.
Under the expanded collaboration, Molecular Partners will lead the development of the six additional programs, with an option for Orano Med to move for the co-development of two of the six programs.
Financial terms were not disclosed.
The company said it expects the deal to have no immediate impact on its fiscal 2025 financial outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.